Mediolanum International Funds Ltd Sells 124,019 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mediolanum International Funds Ltd trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 65.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,787 shares of the medical research company’s stock after selling 124,019 shares during the quarter. Mediolanum International Funds Ltd’s holdings in IQVIA were worth $13,155,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new position in shares of IQVIA in the third quarter worth approximately $28,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $33,000. Finally, Assetmark Inc. raised its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research analyst reports. Truist Financial reduced their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Stephens initiated coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Finally, JPMorgan Chase & Co. cut their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Down 0.2 %

NYSE IQV opened at $201.34 on Friday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.54 billion, a P/E ratio of 26.42, a price-to-earnings-growth ratio of 2.12 and a beta of 1.48. The stock’s 50-day moving average price is $200.42 and its 200-day moving average price is $220.65.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.